HER-2 Positive Breast Cancer Latest Advances

Review Article: Probiotics-Mediated Enhancement of Checkpoint Inhibitor Blockade for HER2+ Breast Cancer.

Journal: Critical reviews in oncogenesis

Published: June 25, 2025

Anti-HER2/Neu Antibody Therapy Inhibits HER2+ Breast Cancer by Blocking Myeloid-Derived Suppressor Cell Activity.

Journal: Oncology research and treatment

Published: June 11, 2025

Nomogram for predicting axillary pathologic complete response after neoadjuvant systemic therapy in HER2 positive and triple negative breast cancer.

Journal: Journal of Cancer

Published: June 04, 2025

Brain Metastases From HER2 Breast Cancer That Achieved Complete Response With Trastuzumab Deruxtecan Without Any Local Treatment.

Journal: Cureus

Published: May 28, 2025

Single-Cell mRNA Analysis for the Identification of Molecular Pathways of IRF1 in HER2+ Breast Cancer.

Journal: Cells

Published: April 15, 2025

Kazakhstani HER2 breast cancer digital image dataset: The ADEL dataset.

Journal: Data in brief

Published: April 09, 2025

Design, novel one-pot green synthesis, and biological evaluation of pyrazolopyridine-congeners selectively targeting HER2+ breast cancer.

Journal: Bioorganic chemistry

Published: March 29, 2025

Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial.

Journal: Cancer letters

Published: March 11, 2025

Immunohistochemical expression of epidermal growth factor receptor: prognostic value in HER2 positive breast cancer.

Journal: Journal of immunoassay & immunochemistry

Published: March 10, 2025

HER3 Expression and PIK3CA Mutational Status Predict Pathological Response of Neoadjuvant Therapy in HER2 Positive Breast Cancer Patients.

Journal: Cancer research and treatment

Published: March 04, 2025

Structural variant and nucleosome occupancy dynamics postchemotherapy in a HER2+ breast cancer organoid model.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 24, 2025

Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

Journal: International journal of molecular sciences

Published: February 23, 2025

Filters

Review Article: Probiotics-Mediated Enhancement of Checkpoint Inhibitor Blockade for HER2+ Breast Cancer.

Review Article: Probiotics-Mediated Enhancement of Checkpoint Inhibitor Blockade for HER2+ Breast Cancer.

Anti-HER2/Neu Antibody Therapy Inhibits HER2+ Breast Cancer by Blocking Myeloid-Derived Suppressor Cell Activity.

Anti-HER2/Neu Antibody Therapy Inhibits HER2+ Breast Cancer by Blocking Myeloid-Derived Suppressor Cell Activity.

Nomogram for predicting axillary pathologic complete response after neoadjuvant systemic therapy in HER2 positive and triple negative breast cancer.

Nomogram for predicting axillary pathologic complete response after neoadjuvant systemic therapy in HER2 positive and triple negative breast cancer.

Brain Metastases From HER2 Breast Cancer That Achieved Complete Response With Trastuzumab Deruxtecan Without Any Local Treatment.

Brain Metastases From HER2 Breast Cancer That Achieved Complete Response With Trastuzumab Deruxtecan Without Any Local Treatment.

Single-Cell mRNA Analysis for the Identification of Molecular Pathways of IRF1 in HER2+ Breast Cancer.

Single-Cell mRNA Analysis for the Identification of Molecular Pathways of IRF1 in HER2+ Breast Cancer.

Kazakhstani HER2 breast cancer digital image dataset: The ADEL dataset.

Kazakhstani HER2 breast cancer digital image dataset: The ADEL dataset.

Design, novel one-pot green synthesis, and biological evaluation of pyrazolopyridine-congeners selectively targeting HER2+ breast cancer.

Design, novel one-pot green synthesis, and biological evaluation of pyrazolopyridine-congeners selectively targeting HER2+ breast cancer.

Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial.

Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial.

Immunohistochemical expression of epidermal growth factor receptor: prognostic value in HER2 positive breast cancer.

Immunohistochemical expression of epidermal growth factor receptor: prognostic value in HER2 positive breast cancer.

HER3 Expression and PIK3CA Mutational Status Predict Pathological Response of Neoadjuvant Therapy in HER2 Positive Breast Cancer Patients.

HER3 Expression and PIK3CA Mutational Status Predict Pathological Response of Neoadjuvant Therapy in HER2 Positive Breast Cancer Patients.

Structural variant and nucleosome occupancy dynamics postchemotherapy in a HER2+ breast cancer organoid model.

Structural variant and nucleosome occupancy dynamics postchemotherapy in a HER2+ breast cancer organoid model.

Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.